In spite of their therapeutic promise in breast and ovarian cancer, the clinical application of PARP inhibitors (PARPis) as an effective treatment has not been widely translated to different cancers, partly because mutations affecting DDR-associated genes are not common in other malignancies, including AML [9, 12–15]. This evidence concerns the gene PARP1 and cancer.